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Inflammation and Atrial Fibrillation
Anthony M. Sideris, MD, Kostas Letsas, MD
A B S T R A C T
There is accumulating evidence pointing to an important association between inflam-
mation and atrial fibrillation (AF). Elevated plasma levels of several markers of the 
inflammatory cascade have been shown to predict future risk of AF. Inflammation 
is likely to represent a novel target for both the treatment and prevention of atrial 
fibrillation.
I N T R O D U C T I O N
Recent advances have raised the hope of effective pharmacological or non-phar-
macological treatments of atrial fibrillation (AF), and of better understanding of the 
pathophysiological mechanisms involved in the initiation and persistence of the ar-
rhythmia. The pathophysiology of AF is complex and multifactorial. The underlying 
etiology is likely different in different patient subpopulations. The development of AF 
leads to many structural and electrical changes contributing to its perpetuation [1]. 
Atrial fibrillation also confers a prothrombotic or hypercoagulable state, which may 
contribute to the risk of thromboembolism [2].
Acute phase response is an innate biological response to a disturbance in homeo-
stasis (infection, inflammation, tissue injury, neoplasm, or immune disturbance). A 
local reaction at the site of injury or infection leads to an activation of cytokines, spe-
cifically interleukin-1 (IL-1), tumor necrosis factor-á (TNF-á), interleukin-6 (IL-6), 
and interferons. Cytokines then trigger systemic responses, which include leukocytosis; 
increases in glucocorticoid production; increases in erythrocyte sedimentation rate, 
fever, activation of complement and clotting cascades and an increase in plasma levels 
of acute phase proteins, C-reactive protein (CRP), serum amyloid A, fibrinogen, and 
other proteins [3].
C-reactive protein is one of the two most abundant acute phase reactants in hu-
mans: levels rapidly increase in the circulation as a result of either trauma or infection. 
Manufactured in the liver and deposited in damaged tissue, CRP is found in high levels 
in inflammatory fluids and in both the intimal layer of the atherosclerotic aortic artery 
and the foam cells within the lesions of atherosclerotic plaque [4,5]. C-reactive protein 
stimulates mononuclear cells to release tissue factor, a protein that is central to the 
initiation of coagulation reactions, complement activation, and the neutralization of 
platelet- activation factor. Together, these reactions promote a thrombotic response [6]. 
C-reactive protein has been traditionally thought of as a bystander marker of vascular 
inflammation, without playing a direct role in the inflammatory process. However, 
recent evidence suggests that CRP may contribute directly to the proinflammatory 
state [7,8]. An increased CRP plasma concentration is strongly associated with the 
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risk of serious cardiovascular events, being the measure of a 
generalized atherosclerotic inflammatory process [9].
I N F L A M M A T O R Y  M A R K E R S
There is accumulating evidence pointing to an important 
association between inflammation and AF. Of all the plasma 
markers of inflammation, CRP has been the most extensively 
investigated in clinical studies. The first observation relating 
inflammation to AF after cardiopulmonary bypass surgery 
was made in 1997 by Bruins et al. They proposed a direct link 
between inflammation and AF by observing an increased fre-
quency of AF after coronary artery bypass surgery. The peak 
incidence of AF occurred on the 2nd-3rd postoperative day, 
coinciding with the maximal elevation of CRP [10].
Inflammatory changes have also been reported in patients 
with non-postoperative AF. Marked inflammatory alterations 
have been observed in atrial specimens obtained from patients 
with isolated persistent AF [11]. Furthermore, Chung, et al 
found that CRP levels were significantly higher in patients with 
paroxysmal and chronic AF than in normal controls, and that 
the level was higher in the chronic AF than in the paroxysmal 
AF group. Thus, they showed that inflammation is involved 
in the onset of AF. However, they stated that whether inflam-
mation is a consequence or a cause of AF remains unknown 
[12]. Some authors suggested the role of inflammation in atrial 
remodelling which promotes the initiation and perpetuation 
of AF [13]. It has been shown that plasma CRP concentration 
is higher in patients with AF, both paroxysmal and persistent, 
compared with the general population [12-14]. An increased 
baseline CRP level is also a risk factor for the development 
of AF during a long-term follow-up period [15]. In one study, 
the combination of microalbuminuria and an elevated hs-CRP 
increased the risk of subsequent AF development by up to 
four-fold [16]. It has also been demonstrated that CRP rep-
resents a robust and significant predictor of early AF relapse 
after succeful cardioversion in patients with AF even after 
adjustment for multiple risk factors, such as hypertension and 
coronary artery disease [14,17,18]. Interestingly, two recent 
studies indicated that CRP relates to the left atrial size and 
AF duration before cardioversion, providing evidence of 
an association between inflammation and atrial structural 
remodelling [19,20].
Another established marker of the inflammatory cascade 
is IL-6. IL-6 is a circulating cytokine produced by monocytes, 
macrophages, lymphocytes and endothelial cells. IL-6 can 
induce a prothrombotic state by increasing expression of fi-
brinogen, tissue factor, factor VIII and von Willebrand factor, 
as well as by activating endothelial cells and increasing platelet 
production [21]. IL-6 is the main hepatic stimulus for CRP 
production [22]. Higher blood levels of IL-6 and fibrinogen 
after coronary artery bypass were observed in patients who de-
veloped AF after surgery. The -174G/C Interleukin-6 promoter 
gene variant appeared to modulate the inflammatory response 
to surgery and to influence the development of postoperative 
AF, suggesting an inflammatory component of postopera-
tive atrial arrhythmias and a genetic predisposition to this 
complication [23]. Similar data have recently been reported 
for patients with non-postoperative AF. Several studies found 
increased levels of IL-6 in patients with AF compared with 
healthy controls [17,19,24-26].
Tumor necrosis factor-á (TNF-á) is a multifunctional 
circulating cytokine derived from endothelial and smooth 
muscle cells as well as macrophages [27,28]. TNF, along with 
interferon-g and IL-1, stimulates IL-6 production by smooth 
muscle cells [29,30]. Sata et al measured TNF-á and other 
indices of inflammation during episodes of paroxysmal AF 
and after the restoration of sinus rhythm in the same patients, 
to clarify the relationship between inflammation and the onset 
of AF. Levels of hs-CRP, IL-6, and TNF after cardioversion 
were significantly higher than those in controls. Furthermore, 
the levels of these indices did not differ significantly even at 
24 hours and 2 weeks after cardioversion. They concluded that 
inflammation is a causative agent of paroxymal AF [25].
A prothrombotic or hypercoagulable state has been 
described in AF, which leads to the high risk of stroke and 
thromboembolism in this condition [1,31-33]. There is an 
apparent link between thrombogenesis and inflammation 
[34-36]. This supports the concept that the observed inflam-
mation in AF increases the risk of thromboembolism as has 
been demonstated for atherosclerotic models. High plasma 
IL-6 levels have been shown to be an independent predictor 
of stroke and the composite end point of stroke and death 
in a prospective study of patients with AF, suggesting that 
inflammation in AF may predict a poor prognosis. Interest-
ingly, trends toward increased risk with high plasma CRP did 
not reach statistical significance [37]. Similarly, Thambidorai 
et al were able to demonstrate in 104 patients with AF that 
clinical and transoesophageal risk factors for stroke were 
greater for patients with elevated CRP compared with those 
with normal levels [38]. This observation is consistent with the 
results reported by Conway et al [26]. A risk score for stroke 
in AF has been correlated with IL-6 [24]. Given the evidence 
so far, the association between markers of inflammation and 
AF suggest that inflammation plays a role in the pathogenesis 
of this arrhythmia.
A N T I - I N F L A M M A T O R Y  I N T E R V E N T I O N S
Drug therapy to prevent AF has traditionally targeted 
atrial electrophysiological mechanisms; however, the proar-
rhythmic effects of such drug therapy have limited its safety. 
An alternative strategy for the prevention of AF would be to 
prevent inflammation.
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G L U C O C O R T I C O I D S
Glucocorticoids are used to treat a wide variety of inflam-
matory diseases. The first observation of a favourable effect 
of corticosteroid treatment on AF was made in 2000 by Yared 
et al [39]. Patients undergoing elective coronary or valvular 
heart surgery were randomized to receive dexamethasone 
or placebo after induction of anesthesia. They found that, 
compared with placebo, patients receiving dexamethasone 
had a lower incidence of new-onset atrial fibrillation during 
the first 3 days postoperatively. However, in another random-
ized, double-blinded, placebo-controlled study, dexametha-
sone failed to decrease the incidence of postoperative atrial 
fibrillation [40]. Dernellis and Panaretou demonstrated that 
the use of low dose glucocorticoids not only improved the 
efficacy of sinus rhythm maintenance postcardioversion but 
was also followed by a fall in CRP levels [14].
S T A T I N S
The use of HMG-CoA reductase inhibitors (statins) in the 
treatment of dyslipidemia has been shown to improve survival 
and significantly reduce the appearance of cardiac events, 
both in primary and secondary prevention [41,42]. Statins also 
have so-called pleiotropic effects, which improve endothelial 
function, reduce inflammation, enhance angiogenesis and vas-
culogenesis, limit oxidative processes, stabilize atherosclerotic 
plaques, and inhibit the thrombogenic response [43,44].
An association between inflammation and AF is undoubt-
edly present. Therefore, therapeutic approaches targeting in-
flammation and oxidative stress may exert favourable effects 
on the risk of AF. Statins have both antiinflammatory and 
antioxidant properties [45,46]. In an animal study, simvastatin 
attenuated AF promotion by atrial tachycardia in dogs, an 
effect not shared by antioxidant vitamins [47]. The available 
evidence tends to prove that statin therapy, which poses anti-
inflammatory properties and reduces CRP levels protects pa-
tients with coronary artery disease from developing AF.This 
effect appeas to be distinct from its cholesterol lowering ability 
[48,49]. Hanna et al analyzed data from Advancent, a large 
multicenter registry of patients with reduced left ventricular 
ejection fraction, to explore the relationship between lipid-
lowering therapy and AF. Lipid-lowering therapy was strongly 
protective against the development of AF. This benefit ap-
peared to be independent of the lipid profile and additive to 
the protective effects of â-blockade and angiotensin convert-
ing enzyme inhibitors (ACEI) or angiotensin receptor blockers 
(ARB) [50]. Similar benefits have been observed in patients 
undergoing coronary artery bypass grafting [51]. C-reactive 
protein lowering with atorvastatin appears to be effective in 
eliminating PAF during daily life in a significant proportion 
of patients [52]. However, in a recent post hoc analysis of a 
large randomized clinical trial, MIRACL study, intensive 
statin treatment did not appear to prevent new AF in the 
16 weeks following acute coronary syndrome [53]. Tveit et al 
also reported that pravastatin did not reduce the recurrence 
rate of AF after electrical cardioversion [54]. Further clinical 
research will determine whether the more widespread use of 
statins will become an important component of the treatment 
of patients with atrial fibrillation.
A N G I O T E N S I N - C O N V E R T I N G  E N Z Y M E  
I N H I B I T O R S  ( A C E I )  A N D  A N G I O T E N S I N  
I I  R E C E P T O R  B L O C K E R S  ( A R B )
Activation of the rennin-angiotensin-aldosterone system 
(RAAS) has been implicated in the pathogenesis of a broad 
spectrum of cardiovascular diseases [55]. Equally, interruption 
of the RAAS by either ACEI and/or ARBs is highly effec-
tive in reducing the known cardiovascular outcomes of these 
diseases [56]. In AF, the RAAS can influence both electrical 
and structural remodelling associated with this arrhythmia 
[55]. There is evidence to date in support of a role for RAAS 
activation as an important factor in the association between 
inflammation and AF. Experimental studies have revealed 
that angiotensin II possesses several proinflammatory prop-
erties, such as the activation of various inflammatory media-
tors (eg, CRP, TNF, IL-6, monocyte chemoattractant protein, 
nuclear factor-kappaB and nuclear factor-alpha), as well as 
stimulating the recruitment and infilitration of neutrophils 
[57,58]. Furthermore, Cardin et al were able to demonstrate 
that increased atrial expression of angiotensin II is linked with 
increased atrial cell death and leukocyte infiltration, again 
supporting a potential link between the RAAS, inflamma-
tion and AF [59]. RAAS blockade elicits anti-iflammatory 
and anti-aggregatory effects in patients with coronary artery 
disease and prevents atherosclerosis and vascular inflamma-
tion [60]. Both ACE-inhibitors and ARBs appear to have 
significant anti-inflammatory actions [61].
Given the potential role of the RAAS in AF, it would be 
rational to suspect that RAAS blockade by ACE inhibitors 
and ARBs may have beneficial effects in AF. Among patients 
enrolled in the SOLVD study of enalapril in left ventricular 
dysfunction, only 5.4% of the patients on enalapril experienced 
AF compared with 24% in the placebo arm. In multivariate 
analysis enalapril was the strongest predictor of reduced AF 
incidence [62]. Healey et al conducted a meta-analysis of the 
available 11 randomized clinical studies on RAAS blockade 
and AF, which included a total of 56,308 patients. They con-
cluded that ACE inhibitors/ARBs reduced the overall risk of 
AF by 28% (P=0.0002). Furthermore, the reduction in AF 
was similarly independent of whether an ACE inhibitor or an 
ARB was the main drug group used (ACE inhibitors: 28%, 
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P=0.01; ARBs: 29%, P=0.00002) [63]. More impressive are 
the data from CHARM and Val-HeFT studies, showing an 
overall 44% relative risk reduction in the development of AF 
among patients with heart failure (P=0.007). The authors also 
noted a clear relationship between worsening heart failure 
(and greater activation of the RAAS system) and greater AF 
prevention [64,65]. Unfortunately, none of the randomized AF 
trials analyzed levels of known inflammatory markers simul-
taneously with the observed beneficial effects in preventing 
either new onset AF or arrhythmia relapse.
P O L Y U N S A T U R A T E D  F A T T Y  A C I D S  
( P U F A )
Evidence from epidemiologic and clinical prevention 
trials suggest that the omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) may have a significant role in protecting against 
death from cardiovascular disease [66-69]. The n-3 PUFAs 
have been shown to exert a range of anti-inflammatory actions 
which include decreased production of arachidonic acid-de-
rived prostaglandins and leukotrienes, decreased production 
of inflammatory cytokines, decreased expression of adhesion 
molecules and decreased expression of degrading proteinases 
that can erode plaque caps [70,71]. As AF has an important 
inflammatory component and n-3 PUFAs are potent anti-
inflammatory agents, recent attention has focused on the 
possible antiarrhythmic effects of PUFA. In cultured rat 
atrial myocytes, n-3 fatty acids reduce induced asynchronous 
contractile activity, suggesting that n-3 fatty acids from fish 
may have antiarrhythmic effects on atrial muscle [72]. Besides 
direct electrophysiological effects, it has been proposed that 
the anti-inflammatory effects of these natural compounds may 
favourably affect atrial remodelling [73]. In a large, prospec-
tive study among elderly adults, greater consumption of tuna 
or other broiled or baked fish was associated with lower risk 
of incident AF. This observed relationship persisted after 
adjustment for a variety of demographic, clinical, lifestyle, 
laboratory, and dietary characteristics, including preced-
ing myocardial infarction and congestive heart failure [74]. 
However, in the Danish Diet, Cancer, and Health study con-
sumption of n-3 fatty acids from fish was not associated with 
a reduction in risk of atrial fibrillation or flutter [75].
A S C O R B I C  A C I D
Antioxidant interventions with vitamin C might have an 
impact against AF-asssociated inflammation. Carnes et al 
were the first to show that an antioxidant intervention with 
vitamin C ameliorates atrial electrical remodeling in experi-
mental animals and significantly reduces the incidence of 
postoperative AF in patients undergoing coronary bypass 
surgery [76]. In a subsequent report examining 46 patients, 
Korantzopoulos et al demonstrated that treatment with vita-
min C reduced the early recurrence of AF after cardioversion 
of persistent AF. In the vitamin C group, CRP levels were 
lower on the seventh day postcardioversion when compared 
with baseline [77].
C O N C L U S I O N
Inflammation plays an important role in the develop-
ment of AF [78-80]. Therefore inflammation may be a new 
therapeutic target in the management of AF. More studies are 
needed to clarify this important issue.
R E F E R E N C E S
 1. Levy S, Sbragia P. Remodelling in atrial fibrillation. Arch Mal 
Coeur 2005; 98:308-12.
 2. Lip GY. Does atrial fibrillation confer a hypercoagulable state? 
Lancet 1995; 346:31-34.
 3. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute 
phase response. Biochem J 1990; 265:621-636.
 4. Ballou SP, Kushner I. C-reactive protein and the acute phase 
response. Adv Intern Med 992; 37:313-336.
 5. Reynolds GD, Vance RP. C-reactive protein immunohisto-
chemical localization in normal and atherosclerotic human 
aortas. Arch Pathol Lab Med 1987; 111:265-269.
 6. Pepys MB. The acute phase response and Creactive protein. 
In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford 
Textbook of Medicine. New York, NY: Oxford University 
Press; 1996:1527-1533.
 7. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The 
major receptor for C-reactive protein on leukocytes is fcg re-
ceptor II. J Exp Med 1999; 190:585–590.
 8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory ef-
fect of C-reactive protein on human endothelial cells. Circula-
tion 2000; 102:2165–2168.
 9. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive pro-
tein as a cardiovascular risk factor. Circulation 1999, 100:96-
102.
 10. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of 
the complement system during and after cardiopulmonary by-
pass surgery: postsurgery activation involves C-reactive protein 
and is associated with postoperative arrhythmia. Circulation 
1997; 96:35428.
 11. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate 
of atrial biopsies in patients with lone atrial fibrillation. Circu-
lation 1997; 96:1180-1184.
 12. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein 
elevation in patients with atrial arrhythmias. Circulation 2001; 
104:2886-91.
 13. Korantzopoulos P, Kolettis T, Siogas K, et al. Atrial fibrillation 
and electrical remodelling: the potential role of inflammation 
132
HOSPITAL CHRONICLES, SUPPLEMENT 2006 INFLAMMATION AND AF
133
and oxidative stress. Med Sci Monit 2003; 9:RA225-229.
 14. Dernellis J, Panaretou M. C-reactive protein and paroxysmal 
atrial fibrillation: evidence of the implication of an inflam-
matory process in paroxysmal atrial fibrillation. Acta Cardiol 
2001; 56:375-80.
 15. Aviles RJ, Martin DO, Apperson- Hansen C, et al. Inflamma-
tion as a risk factor for atrial fibrillation. Circulation 2003, 108:
3006-10.
 16. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, 
van Veldhuisen DJ. C-reactive protein and microalbuminuria 
are associated with atrial fibrillation. Int J Cardiol 2005; 98:
73–77.
 17. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value 
of indexes of inflammation and hypercoagulability on success 
of cardioversion of persistent atrial fibrillation. Am J Cardiol 
2004; 94:50810.
 18. Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity 
C-reactive protein: a novel predictor for recurrence of atrial 
fibrillation after successful cardioversion. J Am Coll Cardiol 
2005; 46(7):1284-7.
 19. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, et al. Re-
lation of elevated C-reactive protein and interleukin-6 levels to 
left atrial size and duration of episodes in patients with atrial 
fibrillation. Am J Cardiol 2005; 95:764–767.
 20. Watanabe T, Takeishi Y, Hirono O, Itoh M, et al. C-reactive 
protein elevation predicts the occurrence of atrial structural re-
modeling in patients with paroxysmal atrial fibrillation. Heart 
Vessels 2005; 20:45–49.
 21. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. 
Br J Hematol 2001; 115:3–12.
 22. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute 
phase response. Biochem J 1990; 265:621– 636.
 23. Gaudino M, Andreotti F, Zamparelli R, Castelnuovo A, et al. 
The 174G/C Interleukin-6 Polymorphism Influences. Postop-
erative Interleukin-6 Levels and Postoperative Atrial Fibril-
lation Is Atrial Fibrillation an Inflammatory Complication? 
Circulation 2003; 108[suppl II]:II-195-II-199.
 24. Roldan V, Marin F, Martinez JG, Garcia-Herola A, et al. Rela-
tion of interleukin-6 levels and prothrombin fragment 1+2 to 
a point-based score for stroke risk in atrial fibrillation. Am J 
Cardiol 2005; 95:881–882.
 25. Sata N, Hamada N, Horinouchi T, Amitani S, et al. C-reactive 
protein and atrial fibrillation. Is inflammation a consequence 
or a cause of atrial fibrillation? Jpn Heart J 2004; 45:441–445.
 26. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of 
interleukin-6 and C-reactive protein to the prothrombotic 
state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43:
2075–2082.
 27. Warner SJ, Libby P. Human vascular smooth muscle cells: 
target for and source of tumor necrosis factor. J Immunol 1989; 
142:100 –109.
 28. Barath P, Fishbein MC, Cao J, Berenson J, et al. Detection and 
localization of tumor necrosis factor in human atheroma. Am J 
Cardiol 1990; 65:297–302.
 29. Ng SB, Tan YH, Guy GR. Differential induction of the inter-
leukin-6 gene by tumor necrosis factor and interleukin-1. J Biol 
Chem 1994; 269:19021–19027.
 30. Sanceau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the 
human interleukin-6 gene by interferon-g and tumor necrosis 
factor-a in monocytic cells involves cooperation between inter-
feron regulatory factor-1, NF kB, and Sp1 transcription factors. 
J Biol Chem 1995; 270:27920–27931.
 31. Lip GYH, Lowe GDO, Rumley A, et al. Increased markers of 
thrombogenesis in chronic atrial fibrillation: effects of warfarin 
treatment. Br Heart J 1995; 73:527–33.
 32. Roldan V, Marın F, Marco P, et al. Hypofibrinolysis in atrial 
fibrillation. Am Heart J 1998; 136:956–60.
 33. Conway DSG, Chin BSP, Pearce LA, et al. Plasma von Wil-
lebrand factor and soluble P-Selectin as indices of endothelial 
damage and platelet activation in 1321 patients with non-valvu-
lar atrial fibrillation: relationship to stroke risk factors. Circula-
tion 2002; 106:1962–2967.
 34. McEver RP. Adhesive interactions of leukocytes, platelets, and 
the vessel wall during hemostasis and inflammation. Thromb 
Haemost 2001; 86:746–56.
 35. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. 
Br J Hematol 2001; 115:3–12.
 36. Joseph L, Fink LM, Hauer-Hensen M. Cytokines in coagula-
tion and thrombosis: a preclinical and clinical review. Blood 
Coagul Fibrinol 2002; 13:105–16.
 37. Conway DSG, Buggins P, Hughes E, Lip GYH. Prognostic 
significance of raised plasma levels of interleukin-6 and C-
reactive protein in atrial fibrillation. Am Heart J 2004; 148:
462–466.
 38. Thambidorai SK, Parakh K, Martin DO, et al. Relation of 
C-reactive protein correlates with risk of thromboembolism in 
patients with atrial fibrillation. Am J Cardiol 2004; 94: 8057
 39. Yared JP, Starr NJ, Torres FK, Bashour CA, et al. Effects of 
single dose, postinduction dexamethasone on recovery after 
cardiac surgery. Ann Thorac Surg 2000;69:1420–1424
 40. Halvorsen P, Raeder J, White PF, Almdahl SL, et al. The effect 
of dexamethasone on side effects after coronary revasculariza-
tion procedures. Anesth Analg 2003; 96(6):1578-83
 41. Shepherd J, Cobe SM, Ford I, Isles CJ, et al. Prevention of 
coronary heart disease with pravastatin in men with hyper-
cholesterolemia. West of Scotland Coronary Prevention Study 
Group. N Engl J Med 1995; 333:1301-7.
 42. MRC/BHF Heart Protection Study of cholesterol lowering 
with simvastatin in 205.536 high-risk individuals: a random-
ized placebo controlled trial. Lancet 2002:360:7-22.
 43. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors. Arterioscler 
Thromb Vasc Biol 2001;21:1712-9
 44. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleio-
tropic effectes of statins: Lipid reduction and beyond. J Clin 
Endocrinol Metab 2002; 87:1451-8.
 45. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends 
Pharmacol Sci 2002; 23:482– 486.
 46. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins pro-
mote potent systemic antioxidant effects through specific in-
132
HOSPITAL CHRONICLES, SUPPLEMENT 2006 INFLAMMATION AND AF
133
flammatory pathways. Circulation 2003; 108:426–431.
 47. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect 
of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation 
Promotion by Atrial-Tachycardia Remodeling in Dogs. Circu-
lation 2004; 110:2313-2319.
 48. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin 
drugs in protecting against atrial fibrillation in patients with 
coronary artery disease. Am J Cardiol 2003; 92:1379-1383.
 49. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reac-
tive protein with cerivastatin among 785 patients with primary 
hypercholesterolemia. Circulation 2001; 103:1191-3.
 50. Hanna IR, Dudley SC Jr, King-Hageman D, Bush H, et al. 
Lipid-lowering therapy reduces the prevalence of atrial fibril-
lation (Abstract). 2005 Heart Rhythm Society Scientific Ses-
sions, May 4–7, 2005, New Orleans, LA, pp. 1–34.
 51. Marin F, Pascual DA, Roldan V, Arribas JM, et al. Statins 
and postoperative risk of atrial fibrillation following coronary 
artery bypass grafting. Am J Cardiol 2006; 97:55-60
 52. Dernellis J, Panaretou M. Effect of C-reactive protein reduc-
tion on paroxysmal atrial fibrillation. Am Heart J 2005; 150:
1064e7–1064e12.
 53. Schwartz GG, Olsson AG, Chaitman B, Goldberger J, et al. 
Effect of intensive statin treatment on the occurrence of atrial 
fibrillation after acute coronary syndrome: an analysis of the 
MIRACL Trial. Circulation 2004; 110(Suppl III):740.
 54. Tveit A, Grundtvig M, Gundersen T, Vanberg P, et al. Analysis 
of pravastatin to prevent recurrence of atrial fibrillation after 
electrical cardioversion. Am J Cardiol 2004; 93:780–782
 55. Freestone B, Beevers DG, Lip GY. The renin–angiotensin–al-
dosterone system in atrial fibrillation: a new therapeutic tar-
get? J Hum Hypertens 2004; 18:461–465.
 56. Choudhury A, Varughese G, Lip GYH. Targeting the Renin 
Angiotensin Aldosterone System in Atrial Fibrillation: a shift 
from electrical to structural therapy? Exp Opin Pharmacother 
2005; 2005; 6:2193-207.
 57. Engelmann MD, Svendsen JH. Inflammation in the genesis 
and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:
2083-2092.
 58. Das UN. Is angiotensin-II an endogenous pro-inflammatory 
molecule? Med Sci Monit 2005; 11: RA155–RA162.
 59. Cardin S, et al. Evolution of the atrial fibrillation substrate in 
experimental congestive heart failure: angiotensin-dependent 
and -independent pathways. Cardiovasc Res 2003; 60:315–325.
 60. da Cunha V, Tham DM, Martin-McNulty B, Deng G, et al. 
Enalapril attenuates angiotensin II-induced atherosclerosis 
and vascular inflammation. Atherosclerosis 2005; 178:9–17.
 61. Schieffer B, Bunte C, Witte J, Hoeper K, et al. Comparative 
effects of AT1-antagonism and angiotensinconverting enzyme 
inhibition on markers of inflammation and platelet aggrega-
tion in patients with coronary artery disease. J Am Coll Cardiol 
2004; 44:362–368.
 62. Vermes E, Tardif J, Bourrassa MG, et al. Enalapril decreases 
the incidence of atrial fibrillation in patients with left ventricu-
lar infarction: insight of the Studies of Left Ventricular Dys-
function (SOLVD) Trials. Circulation 2003; 107:2926-2931.
 63. Healey JS, Baranchuk A, Crystal E, Morillo CA, et al. Preven-
tion of atrial fibrillation with angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers: a meta-analysis. J 
Am Coll Cardiol 2005; 45:1832–1839.
 64. Swedberg K. Prevention of atrial fibrillation in symptomatic 
chronic heart failure by candesartan: results from the CHARM 
study (abstr). J Am Coll Cardiol 2004; 23(Suppl A):222A.
 65. Maggioni AP, Val-HeFT Investigators. Valsartan reduces the 
incidence of atrial fibrillation in patients with heart failure: 
results from the Valsartan Heart Failure Trial (Val-HeFT). 
Am Heart J 2005; 149:548–557.
 66. Rodriguez BL, Sharp DS, Abbott RD, et al. Coronary heart 
disease/atheroslerosis/myocardial Infarction: fish intake may 
limit the increase in risk of coronary heart disease morbidity 
and mortality among heavy smokers: The Honolulu Heart Pro-
gram. Circulation 1996; 94: 952-6.
 67. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett 
WC. Dietary intake of marine n-3 fatty acids, fish intake, and 
the risk of coronary disease among men. N Engl J Med 1995; 
332:977-83.
 68. GISSI-Prevenzione Investigators. Dietary supplementation 
with n-3 polyunsaturated fatty acids and vitamin E after myo-
cardial infarction: results of the GISSI-prevenzione trial. Lan-
cet 1999; 354:447-55.
 69. Marchioli R, Barzi F, Bomba E, et al. Early protection against 
sudden death by n-3 polyunsaturated fatty acids after myocar-
dial infarction. Circulation 2002; 105:1897-1903.
 70. A joint British Journal of Cardiology and H.E.A.R.T UK 
round table meeting held at the National Heart and Lung In-
stitute, 18th November 2003. Omega-3 Polyunsaturated Fatty 
Acids: Mechanisms and Clinical Applications Explored. Br J 
Cardiol 2004; 11(1):16-21.
 71. Thies F, Garry JM, Yaqoob P, Perkasem K, et al. Association of 
n-3 polyunsaturated fatty acids with stability of atherosclerotic 
plaques: a randomised controlled trial. Lancet 2003; 361(9356):
477-85
 72. Jahangiri A, Leifert WR, Patten GS, et al. Termination of asyn-
chronous contractile activity in rat atrial myocytes by n-3 poly-
unsaturated fatty acids. Mol Cell Biochem 2000; 206:33–41.
 73. Korantzopoulos P, Kolettis TM, Goudevenos JA. The anti-
inflammatory and antioxidant effects of long-chain n-3 fatty 
acids or oil-rich fish may favorably affect atrial remodeling in 
atrial fibrillation. Med Hypotheses 2005; 64:1245–1246.
 74. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, et al. Fish 
intake and risk of incident atrial fibrillation. Circulation 2004; 
110:368–373.
 75. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and 
risk of atrial fibrillation or flutter: the Danish Diet, Cancer, 
and Health Study. Am J Clin Nutr 2005; 81:50–54.
 76. Carnes CA, Chung MK, Nakayama T, Nakayama H, et al. 
Ascorbate attenuates atrial pacing-induced peroxynitrite for-
mation and electrical remodelling and decreases the incidence 
of postoperative atrial fibrillation. Circ Res 2001; 89:e32–e38.
 77. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, 
et al. Oral vitamin C administration reduces early recurrence 
134
HOSPITAL CHRONICLES, SUPPLEMENT 2006
rates after electrical cardioversion of persistent atrial fibril-
lation and attenuates associated inflammation. Int J Cardiol 
2005; 102:321–326.
 78. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone 
system in atrial fibrillation: from pathophysiology to clinical 
trials. J Hum Hypertens 2005; 19:855-859.
 79. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an in-
flammatory disorder? Eur Heart J 2006; 27:136-149.
 80. Boos CJ, Lip GY. Prevention of atrial fibrillation by angioten-
sin-converting enzyme inhibitors and angiotensin II receptor 
blockers. J Am Coll Cardiol 2006; 47:889-890.
